Anavex Life Sciences (AVXL) Cash & Equivalents Growth (5y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 22.71% |
| Sep 30, 2025 | 28.53% |
| Jun 30, 2025 | 29.65% |
| Mar 31, 2025 | 34.23% |
| Dec 31, 2024 | 34.48% |
| Sep 30, 2024 | 42.90% |
| Jun 30, 2024 | 45.54% |
| Mar 31, 2024 | 48.26% |
| Dec 31, 2023 | 47.32% |
| Sep 30, 2023 | 45.79% |
| Jun 30, 2023 | 43.07% |
| Mar 31, 2023 | 43.01% |
| Dec 31, 2022 | 38.63% |
| Sep 30, 2022 | 40.30% |
| Jun 30, 2022 | 43.94% |
| Mar 31, 2022 | 45.70% |
| Dec 31, 2021 | 48.17% |
| Sep 30, 2021 | 75.31% |
| Jun 30, 2021 | 74.54% |
| Sep 30, 2020 | 13.85% |
| Jun 30, 2020 | 28.25% |
| Mar 31, 2020 | 33.30% |
| Dec 31, 2019 | 31.51% |
| Sep 30, 2019 | 25.03% |
| Jun 30, 2019 | 21.04% |
| Mar 31, 2019 | 16.18% |
| Dec 31, 2018 | 193.00% |
| Sep 30, 2018 | 131.47% |
| Jun 30, 2018 | 590.53% |
| Mar 31, 2018 | 779.70% |
| Dec 31, 2017 | 222.99% |
| Sep 30, 2017 | 374.88% |
| Jun 30, 2017 | 323.52% |
| Mar 31, 2017 | 165.01% |
| Dec 31, 2016 | 371.52% |
| Sep 30, 2016 | 132.68% |
| Jun 30, 2016 | 51.40% |
| Sep 30, 2015 | 125.08% |